Poison Pill Shareholder Rights Plan: Full Mechanics

Key Takeaways

• A poison pill has five pieces: flip-in dilution, flip-over protection, a threshold (commonly 10–20%), a board redemption right, and a duration (now typically one year).
• Air Products v. Airgas (2011) is the modern benchmark: the Delaware court upheld the pill even against a fully financed, all-cash offer the board deemed inadequate.
• A pill alone is weaker than a pill paired with a staggered board; a hostile bidder can replace a declassified board in one meeting cycle and redeem the pill.
• NOL-protective pills set at 4.99% serve a tax-preservation function under IRC Section 382 and are evaluated differently by proxy advisors than defensive pills.

What It Is

A rights plan distributes one right to each common share. The rights are dormant until a triggering event, typically a person or group acquiring 10 to 20 percent of the company without board approval. On trigger, every shareholder except the acquirer can buy newly issued shares at a steep discount, usually half price. The acquirer's stake is mechanically diluted to a fraction of its former weight, making the takeover prohibitively expensive.

Pills are adopted unilaterally by boards and almost never put to a shareholder vote, which is part of why activists and proxy advisers scrutinize them. They typically last one year (the "modern" duration) but earlier generations ran three to ten years.

The Intuition

The defense does not need to be used to work. The mere existence of a pill forces a hostile bidder to negotiate with the board because going around the board guarantees economic destruction. The board can then run an auction, demand a higher price, or reject the bid entirely.

Critics call this entrenchment. Supporters call it leverage. Both are correct. A pill rebalances the negotiation by giving the board the power to say no. Whether that power is used in shareholders' interest or management's interest depends on the board.

How It Works

A standard pill has five mechanical pieces.

1. The flip-in. When a hostile acquirer crosses the threshold (usually 10 to 20 percent), every other shareholder can purchase additional shares at a discount. The acquirer's rights are voided. Dilution can exceed 50 percent in a single trigger.

2. The flip-over. If the acquirer completes a back-end merger, target shareholders can buy the acquirer's shares at a discount, transferring dilution upward.

3. The trigger threshold. Most modern pills use 10 percent. Lower thresholds (sometimes 4.99 percent) are used to protect net operating loss carryforwards under IRC Section 382.

4. The redemption right. The board can redeem the rights, typically for a nominal amount, before they are triggered. This is what gives the board negotiating leverage. The acquirer must talk to the board to make the pill go away.

5. The duration. A modern shareholder-friendly pill expires after one year. A "morning-after" pill is adopted only when a threat appears.

Under Delaware law, the legality of any defensive measure is reviewed under the Unocal standard: the board must show a reasonable threat and a response proportional to that threat.

Worked Example

In February 2010, Air Products launched a $60 per share all-cash hostile tender offer for Airgas. Airgas had a poison pill and a staggered board. Air Products raised its bid to $70 over the following year and ran a partial proxy contest to elect three Airgas directors, who were nominated specifically to consider redeeming the pill. They were elected, and after deliberation they joined the rest of the board in keeping the pill in place.

Air Products sued. In February 2011 the Delaware Court of Chancery, in Air Products v. Airgas, ruled that the Airgas board had not breached its fiduciary duties in maintaining the pill in the face of an all-cash, fully financed offer the board considered inadequate. Air Products withdrew. Four years later, Air Liquide acquired Airgas at $143 per share, more than double the final hostile offer. The Airgas decision is the modern high-water mark for board authority to "just say no."

Common Mistakes

1. Confusing the trigger with shareholder approval. Pills are adopted by board action alone. Shareholders vote on directors, not on the pill itself, except where bylaws require otherwise.

2. Assuming a pill is permanent. Modern pills expire annually unless renewed. ISS and Glass Lewis penalize directors who renew pills without shareholder approval, particularly above one year.

3. Ignoring the staggered-board interaction. A pill alone is bypassable through a proxy contest replacing the board. A pill plus a classified board is bypassable only over two annual meetings, which is why the combination is so much stronger than either piece.

4. Treating NOL pills as defensive. Pills set at 4.99 percent are generally there to protect tax assets under Section 382, not to block takeovers. Proxy advisers usually evaluate them differently.

5. Reading Airgas as universal license. Airgas turned on the specific board process, advisor opinions, and structural protections. A weaker process can fail the same Unocal scrutiny.

Frequently Asked Questions

Q: What are the five mechanical pieces of a poison pill? A standard rights plan has: (1) a flip-in that dilutes a hostile acquirer who crosses the threshold; (2) a flip-over that lets target holders buy acquirer shares if a back-end merger occurs; (3) a trigger threshold (10–20%); (4) a board redemption right to pull the pill if a bid is acceptable; and (5) a duration (now typically one year). The redemption right is what creates negotiating leverage.

Q: How do poison pills affect hostile takeover analysis? A pill forces any hostile bidder to either negotiate with the board or run a proxy contest to replace enough directors to redeem the pill. Neither path is quick. A pill paired with a staggered board extends that timeline to two annual meeting cycles, which often exceeds financing commitments and buyer patience, the combination kills more bids than pills alone.

Q: What is the Airgas example and why does it matter? Air Products made an all-cash, fully financed offer for Airgas at $60/share in 2010, eventually raising it to $70. Airgas maintained its pill throughout. The Delaware Chancery Court upheld the board's right to "just say no" to an inadequate offer in 2011. Air Products withdrew. Airgas sold to Air Liquide in 2016 at $143/share, more than double the final hostile offer.

Q: How can activists overcome a poison pill? The only reliable paths are: (a) negotiate a bid the board will endorse and redeem the pill for; or (b) run a proxy contest to replace enough directors to control the pill-redemption decision. A staggered board means (b) requires winning at two consecutive annual meetings. Companies without staggered boards are more vulnerable to proxy campaigns.

Q: How is a poison pill deep dive different from the basic poison pill article? The advanced article covers the full five-piece mechanical structure, the Airgas high-water mark for board authority to maintain a pill against a fully financed offer, the NOL-pill variant set at 4.99% under IRC Section 382, and how pill-plus-stagger creates a qualitatively different defensive posture than either piece alone. The intermediate article covers the basic flip-in mechanism and adoption process.

Sources

1. Justia. "Moran v. Household International, Inc., 500 A.2d 1346 (Del. 1985)." https://law.justia.com/cases/delaware/supreme-court/1985/500-a-2d-1346-1.html
2. Justia. "Unocal Corp. v. Mesa Petroleum Co., 493 A.2d 946 (Del. 1985)." https://law.justia.com/cases/delaware/supreme-court/1985/493-a-2d-946-9.html
3. Jones Day. "Delaware Chancery Court Upholds Poison Pill in Takeover Battle for Airgas." https://www.jonesday.com/en/insights/2011/03/delaware-chancery-court-upholds-poison-pill-in-takeover-battle-for-airgas
4. Harvard Law School Forum on Corporate Governance. "The Evolution of the Rights Plan." https://corpgov.law.harvard.edu/2020/04/07/the-evolution-of-the-rights-plan/
5. Wachtell, Lipton, Rosen & Katz. "Takeover Law and Practice." https://www.wlrk.com/docs/takeoverlawandpractice.pdf

Disclaimer

This article is educational content only and is not financial advice. Nothing here is a recommendation to buy, sell, or hold any security. Consult a licensed advisor before making investment decisions.